Cargando…

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

Chimeric antigen receptor-T (CAR-T) cell therapy based on functional immune cell transfer is showing a booming situation. However, complex manufacturing processes, high costs, and disappointing results in the treatment of solid tumors have limited its use. Encouragingly, it has facilitated the devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Ya-Ting, Li, Ya-Ping, He, Xi-Wen, Wang, Xi, Li, Wen-You, Zhang, Yu-Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157406/ https://www.ncbi.nlm.nih.gov/pubmed/37153571 http://dx.doi.org/10.3389/fimmu.2023.1165576

Ejemplares similares

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy
por: Liu, Yilun, et al.
Publicado: (2021)

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
por: Kong, Yingjie, et al.
Publicado: (2023)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)

CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021)

CAR T-cells for colorectal cancer immunotherapy: Ready to go?
por: Ghazi, Bouchra, et al.
Publicado: (2022)

The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
por: González-Brito, Adrián, et al.
Publicado: (2023)

Improving the clinical impact of biomaterials in cancer immunotherapy
por: Gammon, Joshua M., et al.
Publicado: (2016)

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Sloas, Christopher, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
por: Urak, Ryan, et al.
Publicado: (2017)

Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
por: Su, Yang, et al.
Publicado: (2023)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability
por: Hu, Jian-fei, et al.
Publicado: (2022)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future
por: Lin, Ya-Jui, et al.
Publicado: (2022)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
por: Tomasik, Jaromir, et al.
Publicado: (2022)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)

Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification
por: Chen, Yi, et al.
Publicado: (2022)

Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release
por: Zhang, Ang, et al.
Publicado: (2021)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy
por: Chu, Xiao-Dong, et al.
Publicado: (2022)

Recent advances in CAR-T cells therapy for colorectal cancer
por: Qin, Xiaoling, et al.
Publicado: (2022)

Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
por: Shui, Lin, et al.
Publicado: (2020)

Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma
por: Gu, Hui-Yun, et al.
Publicado: (2022)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
por: Jafarzadeh, Leila, et al.
Publicado: (2020)

CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report
por: Sun, Zhuanyi, et al.
Publicado: (2022)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Editorial: Predictive short/long-term efficacy biomarkers and resistance mechanisms of CAR-T immunotherapy treatment
por: Cheng, Jiali, et al.
Publicado: (2023)

Recent advances in CAR-T cell engineering
por: Huang, Ruihao, et al.
Publicado: (2020)

The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
por: Wang, Yu, et al.
Publicado: (2019)

From bench to bedside: the history and progress of CAR T cell therapy
por: Mitra, Aroshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gbhit555cer9ej0l3dci6mitr1